60 related articles for article (PubMed ID: 36480186)
1. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma.
Talluri S; Samur MK; Buon L; Kumar S; Potluri LB; Shi J; Prabhala RH; Shammas MA; Munshi NC
Blood Cancer J; 2021 Oct; 11(10):166. PubMed ID: 34625538
[TBL] [Abstract][Full Text] [Related]
3. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3G protects the genome of human cultured cells and mice from radiation-induced damage.
Britan-Rosich Y; Ma J; Kotler E; Hassan F; Botvinnik A; Smith Y; Moshel O; Nasereddin A; Sharma G; Pikarsky E; Ross S; Kotler M
FEBS J; 2023 Apr; 290(7):1822-1839. PubMed ID: 36325681
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer.
McCann JL; Cristini A; Law EK; Lee SY; Tellier M; Carpenter MA; Beghè C; Kim JJ; Sanchez A; Jarvis MC; Stefanovska B; Temiz NA; Bergstrom EN; Salamango DJ; Brown MR; Murphy S; Alexandrov LB; Miller KM; Gromak N; Harris RS
Nat Genet; 2023 Oct; 55(10):1721-1734. PubMed ID: 37735199
[TBL] [Abstract][Full Text] [Related]
6. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
Cannataro VL; Kudalkar S; Dasari K; Gaffney SG; Lazowski HM; Jackson LK; Yildiz I; Das RK; Gould Rothberg BE; Anderson KS; Townsend JP
Lung Cancer; 2022 Sep; 171():34-41. PubMed ID: 35872531
[TBL] [Abstract][Full Text] [Related]
7. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
8. Learning mutational signatures and their multidimensional genomic properties with TensorSignatures.
Vöhringer H; Hoeck AV; Cuppen E; Gerstung M
Nat Commun; 2021 Jun; 12(1):3628. PubMed ID: 34131135
[TBL] [Abstract][Full Text] [Related]
9. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
[TBL] [Abstract][Full Text] [Related]
10. Targeting APOBECs in cancer: It's about timing.
Hata AN; Larijani M
Cancer Cell; 2024 Apr; 42(4):497-501. PubMed ID: 38593778
[TBL] [Abstract][Full Text] [Related]
11. Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Venkatesan S; Angelova M; Puttick C; Zhai H; Caswell DR; Lu WT; Dietzen M; Galanos P; Evangelou K; Bellelli R; Lim EL; Watkins TBK; Rowan A; Teixeira VH; Zhao Y; Chen H; Ngo B; Zalmas LP; Al Bakir M; Hobor S; Grönroos E; Pennycuick A; Nigro E; Campbell BB; Brown WL; Akarca AU; Marafioti T; Wu MY; Howell M; Boulton SJ; Bertoli C; Fenton TR; de Bruin RAM; Maya-Mendoza A; Santoni-Rugiu E; Hynds RE; Gorgoulis VG; Jamal-Hanjani M; McGranahan N; Harris RS; Janes SM; Bartkova J; Bakhoum SF; Bartek J; Kanu N; Swanton C;
Cancer Discov; 2021 Oct; 11(10):2456-2473. PubMed ID: 33947663
[TBL] [Abstract][Full Text] [Related]
12. APOBEC shapes tumor evolution and age at onset of lung cancer in smokers.
Zhang T; Sang J; Hoang PH; Zhao W; Rosenbaum J; Johnson KE; Klimczak LJ; McElderry J; Klein A; Wirth C; Bergstrom EN; Díaz-Gay M; Vangara R; Colon-Matos F; Hutchinson A; Lawrence SM; Cole N; Zhu B; Przytycka TM; Shi J; Caporaso NE; Homer R; Pesatori AC; Consonni D; Imielinski M; Chanock SJ; Wedge DC; Gordenin DA; Alexandrov LB; Harris RS; Landi MT
bioRxiv; 2024 Apr; ():. PubMed ID: 38617360
[TBL] [Abstract][Full Text] [Related]
13. Evolvability of cancer-associated genes under APOBEC3A/B selection.
Song JH; Dávalos LM; MacCarthy T; Damaghi M
bioRxiv; 2023 Dec; ():. PubMed ID: 38106028
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3 in papillomavirus restriction, evolution and cancer progression.
Warren CJ; Pyeon D
Oncotarget; 2015 Nov; 6(37):39385-6. PubMed ID: 26574726
[No Abstract] [Full Text] [Related]
15. APOBEC3 mutagenesis drives therapy resistance in breast cancer.
Gupta A; Gazzo A; Selenica P; Safonov A; Pareja F; da Silva EM; Brown DN; Zhu Y; Patel J; Blanco-Heredia J; Stefanovska B; Carpenter MA; Pei X; Frosina D; Jungbluth AA; Ladanyi M; Curigliano G; Weigelt B; Riaz N; Powell SN; Razavi P; Harris RS; Reis-Filho JS; Marra A; Chandarlapaty S
bioRxiv; 2024 May; ():. PubMed ID: 38746158
[TBL] [Abstract][Full Text] [Related]
16. Stress-Induced Mutagenesis: Implications in Cancer and Drug Resistance.
Fitzgerald DM; Hastings PJ; Rosenberg SM
Annu Rev Cancer Biol; 2017 Mar; 1():119-140. PubMed ID: 29399660
[TBL] [Abstract][Full Text] [Related]
17. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention.
Poon SL; McPherson JR; Tan P; Teh BT; Rozen SG
Genome Med; 2014; 6(3):24. PubMed ID: 25031618
[TBL] [Abstract][Full Text] [Related]
18. Evolvability of cancer-associated genes under APOBEC3A/B selection.
Song JH; Dávalos LM; MacCarthy T; Damaghi M
iScience; 2024 Apr; 27(4):109433. PubMed ID: 38550998
[TBL] [Abstract][Full Text] [Related]
19. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
20. Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H; Sakhtemani R; Abbasi A; Nikpour N; Stanzione M; Oh S; Langenbucher A; Monroe S; Su W; Cabanos HF; Siddiqui FM; Phan N; Jalili P; Timonina D; Bilton S; Gomez-Caraballo M; Archibald HL; Nangia V; Dionne K; Riley A; Lawlor M; Banwait MK; Cobb RG; Zou L; Dyson NJ; Ott CJ; Benes C; Getz G; Chan CS; Shaw AT; Gainor JF; Lin JJ; Sequist LV; Piotrowska Z; Yeap BY; Engelman JA; Lee JJ; Maruvka YE; Buisson R; Lawrence MS; Hata AN
Nature; 2023 Aug; 620(7973):393-401. PubMed ID: 37407818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
